The roles of anti-Müllerian hormone (AMH) continue to expand, from its discovery as a critical factor in sex determination, through its identification as a regulator of ovarian folliculogenesis, its use in fertility clinics as a measure of ovarian reserve, and its emerging role in hypothalamic-pituitary function. In light of these actions, AMH is considered an attractive therapeutic target to address diverse reproductive needs, including fertility preservation. Here, we set out to characterize the molecular mechanisms that govern AMH synthesis and activity. First, we enhanced the processing of the AMH precursor to >90% by introducing more efficient proprotein convertase cleavage sites (RKKR or ISSRKKRSVSS [SCUT]). Importantly, enhanced processing corresponded with a dramatic increase in secreted AMH activity. Next, based on species differences across the AMH type II receptor-binding interface, we generated a series of human AMH variants and assessed bioactivity. AMH(SCUT) potency (EC(50) 4âng/mL) was increased 5- or 10-fold by incorporating Gln(484) Met/Leu(535) Thr (EC(50) 0.8âng/mL) or Gln(484) Met/Gly(533) Ser (EC(50) 0.4âng/mL) mutations, respectively. Furthermore, the Gln(484) Met/Leu(535) Thr double mutant displayed enhanced efficacy, relative to AMH(SCUT) . Finally, we identified residues within the wrist pre-helix of AMH (Trp(494) , Gln(496) , Ser(497) , and Asp(498) ) that likely mediate type I receptor binding. Mutagenesis of these residues generated gain- (Trp(494) Phe or Gln(496) Leu) or loss- (Ser(497) Ala) of function AMH variants. Surprisingly, combining activating type I and type II receptor mutations only led to modest additive increases in AMH potency/efficacy. Our study is the first to characterize AMH residues involved in type I receptor binding and suggests a step-wise receptor-complex assembly mechanism, in which enhancement in the affinity of the ligand for either receptor can increase AMH activity beyond the natural level.
Characterization of the molecular mechanisms that govern anti-Müllerian hormone synthesis and activity.
阐明控制抗苗勒氏管激素合成和活性的分子机制
阅读:5
作者:Stocker William A, Howard James A, Maskey Shreya, Luan Haitong, Harrison Sophie G, Hart Kaitlin N, Hok Lucija, Thompson Thomas B, Walton Kelly L, Harrison Craig A
| 期刊: | FASEB Journal | 影响因子: | 4.200 |
| 时间: | 2024 | 起止号: | 2024 Jan;38(1):e23377 |
| doi: | 10.1096/fj.202301335RR | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
